Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening
Open Access
- 28 August 2023
- journal article
- research article
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 240, 115644
Abstract
No abstract availableKeywords
Funding Information
- Fundacja na rzecz Nauki Polskiej
- Narodowe Centrum Nauki
This publication has 112 references indexed in Scilit:
- Does the Immune System Naturally Protect Against Cancer?Frontiers in Immunology, 2014
- Novel plasmonic field-enhanced nanoassay for trace detection of proteinsBiosensors and Bioelectronics, 2014
- Cancer Immunotherapy2013
- Tumor Immunotherapy Directed at PD-1New England Journal of Medicine, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Anticancer therapy with checkpoint inhibitors: what, where and when?Trends in Pharmacological Sciences, 2011
- PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1International Immunology, 2010
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProceedings of the National Academy of Sciences, 2002
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996